Ahmed M,
Liu Z,
Lukyanov AN,
et al.
Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.
Radiology 2005;235:469–477.
Bruix J,
Sherman M.
Management of hepatocellular carcinoma.
Hepatology 2005;42:1208–1236.
Bruix J,
Sherman M,
Llovet JM,
et al.
Clinical management of hepatocellular carcinoma.
Conclusions of the Barcelona-2000 EASL conference.
European Association for the Study of the Liver.
J Hepatol 2001;35:421–430.
Choi D,
Lim HK,
Rhim H,
K et al.
Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series.
Eur Radiol 2007;17:684–692.
Goldberg SN,
Girnan GD,
Lukyanov AN,
et al.
Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model.
Radiology 2002;222:797–804.
Lencioni R,
Crocetti L,
Petruzzi P,
et al.
Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study.
J Hepatol 2008; 49: 217–222.
Lewis AL,
Gonzales MV,
Lloyd AW,
et al.
DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.
J Vasc Interv Radiol 2006;17:335–342.
Varela M,
Real MI,
Burrel M,
et al.
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
J Hepatol 2007;46:474–481.
Veltri A,
Moretto P,
Doriguzzi A,
et al.
Radiofrequency thermal ablation (RFA) after transar- terial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).
Eur Radiol 2006;16:661–669.
Yamasaki T,
Kurokawa F,
Shirahashi H,
et al.
Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow.
Comparison with standard percutaneous radiofrequency ablation therapy.
Cancer 2002;95:2353–2360.